• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

诊断性高通量测序知情同意书如何处理非邀约性和次要发现?一项内容分析。

How do consent forms for diagnostic high-throughput sequencing address unsolicited and secondary findings? A content analysis.

机构信息

Department of Public Health and Primary Care, Centre for Biomedical Ethics and Law, KU Leuven, Leuven, Belgium.

Leuven Institute for Human Genomics and Society, Leuven, Belgium.

出版信息

Clin Genet. 2018 Oct;94(3-4):321-329. doi: 10.1111/cge.13391. Epub 2018 Jul 8.

DOI:10.1111/cge.13391
PMID:29888485
Abstract

Whole exome and whole genome sequencing are increasingly being offered to patients in the clinical setting. Yet, the question of whether, and to what extent, unsolicited findings (UF) and/or secondary findings (SF) should be returned to patients remains open and little is known about how diagnostic consent forms address this issue. We systematically identified consent forms for diagnostic genomic sequencing online and used inductive content analysis to determine if and how they discuss reporting of UF and SF, and whether patients are given options regarding the return of these results. Fifty-four forms representing 38 laboratories/clinics were analyzed. A quarter of the forms did not mention UF or SF. Forms used a variety of terms to discuss UF and SF, sometimes using these interchangeably or incorrectly. Reporting policies for UF varied: 5 forms stated that UF will not be returned, 15 indicated UF may be returned, and 28 did not specify their policy. One-third indicated their laboratory returns SF. Addressing inconsistent terminology and providing sufficient information about UF/SF in consent forms will increase patient understanding and help ensure adequate informed consent.

摘要

全外显子组和全基因组测序越来越多地在临床环境中提供给患者。然而,对于是否以及在何种程度上应该向患者返还未请求的发现 (UF) 和/或次要发现 (SF),这个问题仍然悬而未决,而且对于诊断同意书如何解决这个问题知之甚少。我们系统地在线识别了用于诊断基因组测序的同意书,并使用归纳内容分析来确定它们是否以及如何讨论 UF 和 SF 的报告,以及患者是否有权选择返回这些结果。分析了 54 份代表 38 个实验室/诊所的表格。四分之一的表格没有提到 UF 或 SF。表格使用了各种术语来讨论 UF 和 SF,有时会互换或不正确地使用这些术语。UF 的报告政策各不相同:5 份表格表示 UF 将不会被返还,15 份表格表示 UF 可能会被返还,28 份表格没有具体说明其政策。三分之一的表格表示他们的实验室会返还 SF。在同意书中使用一致的术语并提供关于 UF/SF 的足够信息,将提高患者的理解,并有助于确保充分的知情同意。

相似文献

1
How do consent forms for diagnostic high-throughput sequencing address unsolicited and secondary findings? A content analysis.诊断性高通量测序知情同意书如何处理非邀约性和次要发现?一项内容分析。
Clin Genet. 2018 Oct;94(3-4):321-329. doi: 10.1111/cge.13391. Epub 2018 Jul 8.
2
Stakeholder views on secondary findings in whole-genome and whole-exome sequencing: a systematic review of quantitative and qualitative studies.利益相关者对全基因组和全外显子组测序中次要发现的看法:对定量和定性研究的系统评价
Genet Med. 2017 Mar;19(3):283-293. doi: 10.1038/gim.2016.109. Epub 2016 Sep 1.
3
Reporting practices for unsolicited and secondary findings from next-generation sequencing technologies: Perspectives of laboratory personnel.下一代测序技术中主动和次要发现的报告实践:实验室人员的观点。
Hum Mutat. 2017 Aug;38(8):905-911. doi: 10.1002/humu.23259. Epub 2017 Jun 6.
4
Mainstreaming informed consent for genomic sequencing: A call for action.将基因组测序知情同意纳入主流:行动呼吁。
Eur J Cancer. 2021 May;148:405-410. doi: 10.1016/j.ejca.2021.02.029. Epub 2021 Mar 27.
5
Understanding variations in secondary findings reporting practices across U.S. genome sequencing laboratories.了解美国基因组测序实验室次要发现报告实践的差异。
AJOB Empir Bioeth. 2018 Jan-Mar;9(1):48-57. doi: 10.1080/23294515.2017.1405095. Epub 2017 Dec 21.
6
Uncertain futures and unsolicited findings in pediatric genomic sequencing: guidelines for return of results in cases of developmental delay.儿科基因组测序中的不确定未来和意外发现:发育迟缓病例中结果回报的指南。
BMC Med Ethics. 2023 Nov 11;24(1):98. doi: 10.1186/s12910-023-00977-y.
7
Content Analysis of Informed Consent for Whole Genome Sequencing Offered by Direct-to-Consumer Genetic Testing Companies.直接面向消费者的基因检测公司提供的全基因组测序知情同意书的内容分析
Hum Mutat. 2016 Dec;37(12):1248-1256. doi: 10.1002/humu.23122. Epub 2016 Oct 5.
8
Informed consent for exome sequencing research in families with genetic disease: the emerging issue of incidental findings.遗传病家族外显子组测序研究的知情同意:偶然发现这一新兴问题。
Am J Med Genet A. 2014 Nov;164A(11):2745-52. doi: 10.1002/ajmg.a.36706. Epub 2014 Sep 22.
9
Informed consent for exome sequencing in diagnostics: exploring first experiences and views of professionals and patients.诊断中全外显子测序的知情同意:探索专业人员和患者的初步经验与观点。
Clin Genet. 2014 May;85(5):417-22. doi: 10.1111/cge.12299. Epub 2013 Nov 4.
10
Reflecting on earlier experiences with unsolicited findings: points to consider for next-generation sequencing and informed consent in diagnostics.反思早期在非预期发现方面的经验:下一代测序和诊断知情同意中的注意要点。
Hum Mutat. 2013 Oct;34(10):1322-8. doi: 10.1002/humu.22370. Epub 2013 Jul 16.

引用本文的文献

1
Consent for genomic sequencing: a conversation, not just a form.基因组测序的知情同意:这是一场对话,而不仅仅是一张表格。
Eur J Hum Genet. 2025 Apr;33(4):397-398. doi: 10.1038/s41431-025-01805-0. Epub 2025 Mar 3.
2
Hope, but never expect? Comparing parents' pre- and post-disclosure attitudes toward return of results from diagnostic exome sequencing for their child.抱有希望,但不要期望过高?比较父母在对孩子进行外显子组测序诊断后披露结果前后的态度。
Mol Genet Genomic Med. 2024 Mar;12(3):e2341. doi: 10.1002/mgg3.2341. Epub 2024 Feb 17.
3
A framework for reporting secondary and incidental findings in prenatal sequencing: When and for whom?
产前测序中次要和偶然发现的报告框架:何时以及为谁报告?
Prenat Diagn. 2022 May;42(6):697-704. doi: 10.1002/pd.6097. Epub 2022 Jan 19.
4
The full spectrum of ethical issues in pediatric genome-wide sequencing: a systematic qualitative review.儿科全基因组测序中的伦理问题全景:系统定性综述。
BMC Pediatr. 2021 Sep 6;21(1):387. doi: 10.1186/s12887-021-02830-w.
5
Should we respect parents' views about which results to return from genomic sequencing?我们是否应该尊重父母对基因测序结果的看法?
Hum Genet. 2022 May;141(5):1059-1068. doi: 10.1007/s00439-021-02293-0. Epub 2021 May 13.
6
Clinical management, ethics and informed consent related to multi-gene panel-based high throughput sequencing testing for platelet disorders: Communication from the SSC of the ISTH.与基于多基因panel的血小板疾病高通量测序检测相关的临床管理、伦理及知情同意:国际血栓与止血学会科学标准化委员会的沟通文件
J Thromb Haemost. 2020 Oct;18(10):2751-2758. doi: 10.1111/jth.14993.
7
Old Challenges or New Issues? Genetic Health Professionals' Experiences Obtaining Informed Consent in Diagnostic Genomic Sequencing.旧挑战还是新问题?遗传健康专业人员在诊断性基因组测序中获得知情同意的经验。
AJOB Empir Bioeth. 2021 Jan-Mar;12(1):12-23. doi: 10.1080/23294515.2020.1823906. Epub 2020 Oct 5.
8
Criteria for reporting incidental findings in clinical exome sequencing - a focus group study on professional practices and perspectives in Belgian genetic centres.临床外显子测序中偶然发现报告标准 - 比利时遗传中心专业实践和观点的焦点小组研究。
BMC Med Genomics. 2019 Aug 20;12(1):123. doi: 10.1186/s12920-019-0561-0.
9
Consent for clinical genome sequencing: considerations from the Clinical Sequencing Exploratory Research Consortium.临床基因组测序同意书:来自临床测序探索性研究联盟的考虑因素。
Per Med. 2019 Jul;16(4):325-333. doi: 10.2217/pme-2018-0076. Epub 2019 Jul 17.
10
Attitudes toward genomic tumor profiling tests in Japan: patients, family members, and the public.日本对基因组肿瘤分析检测的态度:患者、家属和公众。
J Hum Genet. 2019 May;64(5):481-485. doi: 10.1038/s10038-018-0555-3. Epub 2019 Jan 10.